Company: TELO
Filing Date: 2025-06-05
Form Type: 8-K
Source: 0001641172-25-013711
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-06-05
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation
in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Treatment
restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and
resulted in 100% survival - highlighting Telomir-1’s potential to reverse key hallmarks of aging

On
June 5, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), an emerging leader in age-reversal science, announced new data from a preclinical
study of its lead compound, Telomir-1, in a validated animal model of Werner Syndrome (WS), an ultra-rare genetic disorder characterized
by premature aging and shortened lifespan.

The
data showed that oral administration of Telomir-1 reset key biological aging markers by restoring healthy DNA methylation

Telomir-1
reversed this dysfunction by restoring methylation at two CpG island regions associated with the epigenetic clock, effectively resetting
the gene regulation system. The study also demonstrated:

  A significant                                                               
  increase in telomere length, exceeding levels observed in healthy controls  
 ──────────────────────────────────────────────────────────────────────────────
  Full reversal of muscle                                                     
  Up to 50% reduction in                                                      
  100% survival in all Telomir-1                                              

These
findings confirm and build upon Telomir Pharmaceuticals’ previously reported results in a C. elegans

The
Company believes these data support the continued development of Telomir-1 as a novel therapeutic candidate targeting the fundamental
mechanisms of aging-related diseases, including those driven by telomere dysfunction and epigenetic instability.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                           TELOMIR PHARMACEUTICALS, INC.                               
  Dated: June 5, 2025      By:                                /s/                      
                           Name:                              Erez Aminov              
                           Title:                             Chief Executive Officer